Back

Bionano Genomics stock surges 15.79% on growth plan, reimbursement and regulatory milestones

Verifying
  • Bionano Genomics management outlined a multi-year growth strategy at the H.C. Wainwright conference.
  • 2027 revenue is projected at $50 million to $54 million, according to management.
  • Bionano Laboratories announced a proposed MolDX Medicare coverage determination on Sept. 10.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Bionano Genomics stock surges 15.79% on growth plan, reimbursement and regulatory milestones - CoinPost Terminal